**Traders heavily favor "No" at 91.5% because ongoing genomic surveillance shows SARS-CoV-2 continuing to evolve through incremental changes within established Omicron-derived lineages rather than producing a new variant of concern.** As of late July 2026, the WHO lists several variants under monitoring—such as XFG, NB.1.8.1, BA.3.2, and the recently designated PQ.16.1.1—but none meet the criteria for a variant of concern, with risk assessments indicating limited impact on transmissibility, severity, or vaccine effectiveness against severe disease. Recent summer 2026 activity reflects a modest uptick in cases driven by these familiar sublineages, including dominant strains like XFG.1.1, without signs of a major antigenic shift that would trigger new designations. Updated 2026-2027 vaccine formulations target circulating JN.1-lineage viruses like XFG, reflecting broad population immunity from prior infections and vaccinations that appears to constrain rapid emergence of highly concerning strains. With only a few months remaining until 2027 and no escalation in monitored lineages over the past several weeks, the market reflects consensus that a qualifying new variant of concern is unlikely in the near term.